BioSpace News Archive

The Honourable Mona Fortier, Member of Parliament for Ottawa - Vanier and Minister of Middle Class Prosperity and Associate Minister of Finance, on behalf of the Honourable Patty Hajdu, Minister of Health, will highlight Government of Canada funding to support a safer supply project in Ottawa . Date Thursday, October 15, 2020 T

GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its third quarter earnings results after market close on Wednesday, October 28, 2020.

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients.

In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the course of disease1

FEP Blue Focus® premiums remain unchanged for third consecutive year, while the program introduces changes across all products to expand access to care [14-October-2020] WASHINGTON , Oct. 14, 2020 /PRNewswire/ -- Today, the Blue Cross® and Blue Shield® Federal Employee Program ® (FEP ® ) announced 2021 benefits, including newly expanded telemedicine benefits, along w

Mallinckrodt plc announced that it has received approvals from the U.S. Bankruptcy Court for the District of Delaware for its “First Day” motions related to the Company’ s voluntary Chapter 11 petitions filed on October 12, 2020.

SI-BONE, Inc. announced the pricing of its underwritten public offering of 3,190,053 shares of its common stock at a price to the public of $22.00 per share.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients’ lives, today announced that the company will report 2020 third quarter financial results on Thursday, October 22, 2020, after market close.

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces enrollment of the 10 th subject in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD). “Patient screening and enroll

The Public Health Agency of Canada is collaborating with provincial and territorial public health and food safety partners to investigate an outbreak of Vibrio parahaemolyticus infections occurring in four provinces.